University of Winnipeg research aims to identify resistance to breast cancer treatment

Issue: BCMJ, vol. 60 , No. 7 , September 2018 , Pages 350 News

A simple test could improve the treatment odds of patients diagnosed with breast cancer, thanks to new research at the University of Winnipeg.

The drug Tamoxifen, used to treat the majority of breast cancer cases, is ineffective in approximately half of all patients who receive it. Dean Reddick, a graduate student in the Master of Science in Bioscience, Technology and Public Policy program, is researching a way to identify these patients before treatment starts.

The research impacts the treatment of estrogen receptor positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancer cases, and is characterized by estrogen binding to an abnormal number of receptors. Doctors typically prescribe Tamoxifen at the start of any ER+ treatment, thanks to its success rate in patients who are responsive to it.

Key to solving the issue is a protein within cancer cells known as N-Myristoyltransferase (NMT), which the lab has already discovered activates with increased estrogen receptor activity. Since last September, Reddick has produced 14 different variants of breast cancer cells, each with different localizations of the protein. The plan is now to treat each one and monitor their responses. Although the lab still has further testing to do, Reddick believes the protein is an indicator of responsive cells. Once the indicators are identified, Reddick says within 3 to 4 years a biopsy could be used to determine a patient’s resistance level and prescribe appropriate treatment.

. University of Winnipeg research aims to identify resistance to breast cancer treatment. BCMJ, Vol. 60, No. 7, September, 2018, Page(s) 350 - News.

Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.

For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit

BCMJ Guidelines for Authors

Leave a Reply